This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported ...

This presentation discusses DME management, focusing on transitioning to high-dose aflibercept following suboptimal responses ...

Alteogen Inc. a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics, announced that the European Commission (EC) has granted marketing ...

The Ontario Drug Benefit (ODB) Formulary is the official listing that determines which prescription medicines are covered under the public insurance system in Ontario, Canada's largest province. This ...

Sandoz has reached an agreement with Regeneron, to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz aflibercept biosimilar. Patent ...

BMW Motorrad is back at the drawing board, dreaming up a wild two-wheeler concept that I'd love to see it bring to life post-haste. With its seat-belt-equipped bench and roll cage, the Vision CE is ...

MARLBOROUGH, Mass., September 04, 2025--(BUSINESS WIRE)--At CE Pharm, SCIEX, a global leader in life science analytical technologies, launches new native fluorescence detection on the BioPhase 8800 ...

At CE Pharm, SCIEX, a global leader in life science analytical technologies, launches new native fluorescence detection on the BioPhase 8800 system. To ensure drug safety and efficacy, multiple ...

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...